Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 14/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21912851 | 0.90 | BCHE (0.50) | KDM1ABCHEPDE4APDE4BPDE4C | |
| SCHEMBL3237107 | 0.89 | KDM1A (0.49) | KDM1ABCHEPDE4APDE4BPDE4C | |
| SCHEMBL3237114 | 0.89 | KDM1A (0.49) | KDM1ABCHEPDE4APDE4BPDE4C | |
| SCHEMBL30681524 | 0.88 | BCHE (0.48) | KDM1ABCHEPDE4APDE4BPDE4C | |
| SCHEMBL21912451 | 0.88 | BCHE (0.48) | KDM1ABCHEPDE4APDE4BPDE4C | |
| SCHEMBL4775639 | 0.84 | BCHE (0.45) | KDM1ABCHEPDE4APDE4BPDE4C | |
| SCHEMBL30901783 | 0.81 | BCHE (0.47) | KDM1ABCHEPDE4APDE4BPDE4C | |
| SCHEMBL27212944 | 0.81 | BCHE (0.42) | KDM1ABCHEPDE4APDE4BPDE4C | |
| SCHEMBL6745177 | 0.81 | KDM1A (0.43) | KDM1ABCHEPDE4APDE4BPDE4C | |
| SCHEMBL13360857 | 0.80 | KDM1A (0.43) | KDM1ABCHEOPRK1HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723350-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2010-05-25 | — | — | US | disclosed |
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR10, CXCR2 | KDM1A 4359/4885BCHE 4809/4885PDE4A 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.